©The Author(s) 2026.
World J Hepatol. Feb 27, 2026; 18(2): 114346
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114346
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114346
Table 1 Baseline characteristics of the study population before and after propensity score matching, median (interquartile range)/n (%)/mean ± SD
| Variables | Before matching (n = 187) | After matching (n = 144) | ||||
| ETV (n = 139) | TMF (n = 48) | P value | ETV (n = 96) | TMF (n = 48) | P value | |
| Age (year) | 36 (30-45) | 36 (31-46) | 0.914 | 35 (29-45) | 36 (31-46) | 0.624 |
| Age (year) | 0.754 | 0.198 | ||||
| < 30 | 35 (25.18) | 11 (22.92) | 32 (33.33) | 11 (22.92) | ||
| ≥ 30 | 104 (74.82) | 37 (77.08) | 64 (66.67) | 37 (77.08) | ||
| Male (%) | 79 (56.83) | 32 (66.67) | 0.232 | 55 (57.29) | 32 (66.67) | 0.278 |
| DNA (log10IU/mL) | 4.66 (3.28-7.29) | 4.51 (3.34-7.59) | 0.714 | 5.24 (3.31-7.80) | 4.51 (3.34-7.59) | 0.788 |
| HBsAg (log10IU/mL) | 3.28 (2.59-3.72) | 3.66 (3.07-4.37) | 0.011 | 3.50 (3.07-4.00) | 3.66 (3.07-4.37) | 0.431 |
| HBeAg positive | 53 (38.13) | 21 (43.75) | 0.492 | 46 (47.92) | 21 (43.75) | 0.637 |
| TBIL (μmol/L) | 16.0 (11.6-23.5) | 15.9 (11.9-23.7) | 0.951 | 15.8 (12.1-22.9) | 15.8 (11.9-23.7) | 0.953 |
| Alb (g/L) | 45.4 (43.0-47.2) | 44.8 (42.5-45.9) | 0.084 | 45.6 (43.0-47.5) | 44.8 (42.4-45.9) | 0.089 |
| ALT (U/L) | 49.0 (27.4-82.2) | 45.8 (29.2-74.8) | 0.977 | 53.2 (29.0-87.8) | 45.8 (29.2-74.8) | 0.442 |
| AST (U/L) | 35.5 (26.6-63.5) | 35.9 (24.1-57.1) | 0.740 | 37.7 (28.2-65.8) | 35.9 (24.1-57.1) | 0.412 |
| GGT (U/L) | 27.0 (16.0-50.0) | 31.2 (18.3-59.5) | 0.178 | 27.0 (17.0-53.7) | 31.2 (18.2-59.5) | 0.335 |
| ALP (U/L) | 78.0 (65.4-95.1) | 86.4 (68.6-101.2) | 0.185 | 79.7 (65.7-95.7) | 86.4 (68.6-101.2) | 0.297 |
| TG (mmol/L) | 1.13 (0.79-1.60) | 1.24 (0.86-1.75) | 0.327 | 1.07 (0.80-1.62) | 1.24 (0.86-1.75) | 0.285 |
| TC (mmol/L) | 4.41 (3.84-5.05) | 4.53 (4.05-4.76) | 0.644 | 4.43 (3.88-4.86) | 4.53 (4.05-4.76) | 0.550 |
| FBG (mmol/L) | 5.00 (4.68-5.35) | 5.00 (4.76-5.29) | 0.782 | 5.00 (4.68-5.35) | 5.00 (4.76-5.29) | 0.656 |
| SCr (μmol/L) | 65.51 ± 13.47 | 67.01 ± 11.12 | 0.449 | 66.48 ± 14.14 | 67.01 ± 11.12 | 0.805 |
| eGFR (mL/minute/1.73 m2) | 112.14 ± 9.87 | 112.50 ± 10.28 | 0.830 | 111.83 ± 10.16 | 112.50 ± 10.28 | 0.712 |
| BUN (mmol/L) | 4.21 ± 1.00 | 4.33 ± 1.11 | 0.514 | 4.18 ± 1.00 | 4.33 ± 1.11 | 0.430 |
| HGB (g/L) | 145 (134-159) | 147 (135-159) | 0.482 | 148 (135-159) | 147 (135-159) | 0.887 |
| PLT (× 109/L) | 199 ± 60 | 196 ± 55 | 0.695 | 201 ± 60 | 196 ± 55 | 0.574 |
| LSM (kPa) | 6.9 (5.6-9.9) | 7.0 (6.0-7.7) | 0.574 | 7.2 (6.0-10.3) | 7.0 (6.0-7.6) | 0.232 |
| Liver cirrhosis | 15 (10.79) | 5 (10.42) | 0.942 | 10 (10.42) | 5 (10.42) | 1.000 |
- Citation: Ma SP, Wang L, Zhang YL, Wan X, Liu Q, Tang YL, Malhi LR, Ge SF. Effects of tenofovir amibufenamide and entecavir on estimated glomerular filtration rate in treatment-naïve patients with chronic hepatitis B. World J Hepatol 2026; 18(2): 114346
- URL: https://www.wjgnet.com/1948-5182/full/v18/i2/114346.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i2.114346